AU2018246292A1 - Prevention and treatment of non-melanoma skin cancer (NMSC) - Google Patents

Prevention and treatment of non-melanoma skin cancer (NMSC) Download PDF

Info

Publication number
AU2018246292A1
AU2018246292A1 AU2018246292A AU2018246292A AU2018246292A1 AU 2018246292 A1 AU2018246292 A1 AU 2018246292A1 AU 2018246292 A AU2018246292 A AU 2018246292A AU 2018246292 A AU2018246292 A AU 2018246292A AU 2018246292 A1 AU2018246292 A1 AU 2018246292A1
Authority
AU
Australia
Prior art keywords
mrna
ifn
seq
utr
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2018246292A
Other languages
English (en)
Inventor
Markus Mandler
Frank Mattner
Walter Schmidt
Achim Schneeberger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Accanis Biotech F&e & Co KG GmbH
Original Assignee
Accanis Biotech F&e & Co KG GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Accanis Biotech F&e & Co KG GmbH filed Critical Accanis Biotech F&e & Co KG GmbH
Publication of AU2018246292A1 publication Critical patent/AU2018246292A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Media Introduction/Drainage Providing Device (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Medicinal Preparation (AREA)
AU2018246292A 2017-03-31 2018-03-29 Prevention and treatment of non-melanoma skin cancer (NMSC) Abandoned AU2018246292A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP17164257 2017-03-31
EP17164257.2 2017-03-31
EP17200162.0 2017-11-06
EP17200162 2017-11-06
PCT/EP2018/058036 WO2018178215A1 (en) 2017-03-31 2018-03-29 Prevention and treatment of non-melanoma skin cancer (nmsc)

Publications (1)

Publication Number Publication Date
AU2018246292A1 true AU2018246292A1 (en) 2019-10-10

Family

ID=61763994

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018246292A Abandoned AU2018246292A1 (en) 2017-03-31 2018-03-29 Prevention and treatment of non-melanoma skin cancer (NMSC)

Country Status (8)

Country Link
US (1) US20200038487A1 (cg-RX-API-DMAC7.html)
EP (2) EP4019037A1 (cg-RX-API-DMAC7.html)
JP (1) JP7264867B2 (cg-RX-API-DMAC7.html)
KR (1) KR20190133216A (cg-RX-API-DMAC7.html)
CN (1) CN110636854A (cg-RX-API-DMAC7.html)
AU (1) AU2018246292A1 (cg-RX-API-DMAC7.html)
CA (1) CA3057768A1 (cg-RX-API-DMAC7.html)
WO (1) WO2018178215A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101987591B1 (ko) * 2018-08-06 2019-06-10 국립해양생물자원관 인게놀 메부테이트에 특이적으로 결합하는 핵산 앱타머 및 그 용도
US11685766B2 (en) 2019-05-08 2023-06-27 Creighton University 14-3-3 targeting peptides for cancer treatment
US11518784B2 (en) 2019-05-08 2022-12-06 Creighton University 14-3-3 targeting peptides for cancer treatment
NL2025475B1 (en) * 2020-04-30 2021-11-09 Ribopro B V Rna molecules with decreased immunogenicity and methods for reducing rna immunogenicity
CN115887495A (zh) * 2022-07-11 2023-04-04 上海默多赛生物科技有限公司 化学修饰的mRNA转染的皮片或皮瓣及其促进创面愈合的用途
CN116785501A (zh) * 2022-08-04 2023-09-22 上海交通大学医学院附属上海儿童医学中心 促进心脏组织修复的modRNA转染改造的细胞及其应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA873743B (en) * 1986-05-27 1987-11-25 Schering Corporation Treatment of basal cell carcinoma intralesionally with recombinant human alpha interferon
US5028422A (en) 1986-05-27 1991-07-02 Schering Corporation Treatment of basal cell carcinoma intralesionally with recombinant human alpha interferon
US5002764A (en) 1986-08-12 1991-03-26 Schering Corporation Treatment of actinic keratoses with alpha2 interferon
WO1990000406A1 (en) 1988-07-05 1990-01-25 Schering Corporation Treatment of genital warts with a combination of podophyllin and recombinant dna human alpha interferon
US4959210A (en) 1988-11-01 1990-09-25 Schering Corporation Treatment of genital warts with a combination of liquid nitrogen and recombinant DNA human alpha interferon
IL129387A0 (en) 1996-10-18 2000-02-17 Canji Inc Methods and compositions for delivery and expression of interferon-alpha nucleic acids
CA2323604A1 (en) 1998-03-19 1999-09-23 Valentis, Inc. Interferon alpha plasmids and delivery systems, and methods of making and using the same
KR20020018197A (ko) 1999-05-19 2002-03-07 추후보정 Fc 융합 단백질로서의 인터페론-알파 단백질의 발현 및분비
ATE291925T1 (de) * 2001-06-05 2005-04-15 Curevac Gmbh Stabilisierte mrna mit erhöhtem g/c-gehalt und optimierter codon usage für die gentherapie
ES2302402B1 (es) 2005-06-16 2009-05-08 Proyecto De Biomedicina Cima, S.L. Uso de una citoquina de la familia de interleuquina-6 en la preparacion de una composicion para administracion combinada con interferon-alfa.
WO2009030464A2 (de) 2007-09-08 2009-03-12 Bayer Schering Pharma Aktiengesellschaft HERSTELLUNG UND VERWENDUNG VON VARIANTEN HUMANER KUNITZ-TYP PROTEASE-INHIBITOREN (hKTPI)
WO2010037408A1 (en) 2008-09-30 2010-04-08 Curevac Gmbh Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
WO2013151664A1 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins
WO2013143555A1 (en) 2012-03-26 2013-10-03 Biontech Ag Rna formulation for immunotherapy
KR102311614B1 (ko) 2013-03-14 2021-10-08 샤이어 휴먼 지네틱 테라피즈 인크. Cftr mrna 조성물 및 관련 방법 및 사용
WO2015062738A1 (en) 2013-11-01 2015-05-07 Curevac Gmbh Modified rna with decreased immunostimulatory properties
KR102415811B1 (ko) 2014-01-31 2022-07-04 팩터 바이오사이언스 인크. 핵산 제조 및 송달을 위한 방법 및 산물
US11241505B2 (en) * 2015-02-13 2022-02-08 Factor Bioscience Inc. Nucleic acid products and methods of administration thereof
CA2990881C (en) 2015-06-30 2024-02-20 Ethris Gmbh Utrs increasing the translation efficiency of rna molecules

Also Published As

Publication number Publication date
EP3600379A1 (en) 2020-02-05
CN110636854A (zh) 2019-12-31
JP2020515644A (ja) 2020-05-28
CA3057768A1 (en) 2018-10-04
KR20190133216A (ko) 2019-12-02
JP7264867B2 (ja) 2023-04-25
US20200038487A1 (en) 2020-02-06
EP3600379B1 (en) 2022-12-21
WO2018178215A1 (en) 2018-10-04
EP4019037A1 (en) 2022-06-29

Similar Documents

Publication Publication Date Title
EP3600379B1 (en) Prevention and treatment of non-melanoma skin cancer (nmsc)
CN103003427B (zh) 具有佐剂活性的新型核酸及其应用
JP2003525222A (ja) Il−12をコードする核酸分子の腫瘍内投与
US20200369738A1 (en) Treatment of Local Skin Hypotrophy Conditions
JP5667043B2 (ja) 阻害性オリゴヌクレオチドを送達するための組成物および方法
CN110592222B (zh) Triml1作为肝癌的分子标记物的应用
HK40067000A (en) Prevention and treatment of non-melanoma skin cancer (nmsc)
US20180117176A1 (en) Porous silicon microparticle-based cancer vaccines and methods for potentiating anti-tumor immunity
Liu et al. Overexpression of interleukin-18 induces growth inhibition, apoptosis and gene expression changes in a human tongue squamous cell carcinoma cell line
JP5397692B2 (ja) 悪性黒色腫抗原の発現上昇剤及びその用途
JP2017082002A (ja) 核酸移送担体
AU2006325752B2 (en) Use of eIF-5A to kill multiple myeloma cells
CN104511028A (zh) Klf9基因在抑制肝癌中的应用
Cao Intrapericardial Delivery of a ROS-Responsive Hydrogel Encapsulating FAP-Specific CAR-T Cells for Localized Treatment of Cardiac Fibrosis
JP2017200914A (ja) ケモカインcxcl14を利用した自然免疫活性化アジュバント
Zhang et al. IFN-γ Enhances the Efficacy of Exosomes Derived from Mesenchymal Stem Cells in Myocardial Infarction Rats via miR-21 Stimulated by STAT1
KR20250109232A (ko) 포유류에서 엘라스틴 신생합성을 유도하기 위한 코돈 최적화 올리고뉴클레오티드
CN101007836A (zh) 核酸分子rtn4bsr52及其在制备抗癌药物中的应用
WO2025110115A1 (ja) Cxcl12 rna配列に基づく新規二本鎖rna及びその利用
CN103215256B (zh) 一种具有肿瘤细胞抑制功能的多核苷酸
WO2022141406A1 (zh) 一种能够提供治疗有效量的白介素10的试剂及其抗肿瘤应用
CN101007838A (zh) 核酸分子rtn4bsr22及其在制备抗癌药物中的应用
CN101007837A (zh) 核酸分子rtn4bsr42及其在制备抗癌药物中的应用
CN101328475A (zh) 核酸分子nrn1sr1及其在制备抗癌药物中的应用
CN101302510A (zh) 一种核酸分子及其在制备抗癌药物中的应用

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted